WO2000071101A3 - Methods and compounds for inhibiting amyloid deposits - Google Patents

Methods and compounds for inhibiting amyloid deposits Download PDF

Info

Publication number
WO2000071101A3
WO2000071101A3 PCT/CA2000/000607 CA0000607W WO0071101A3 WO 2000071101 A3 WO2000071101 A3 WO 2000071101A3 CA 0000607 W CA0000607 W CA 0000607W WO 0071101 A3 WO0071101 A3 WO 0071101A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
deposits
compositions
iapp
compounds
Prior art date
Application number
PCT/CA2000/000607
Other languages
French (fr)
Other versions
WO2000071101A2 (en
Inventor
Walter A Szarek
Donald E Weaver
Xianqi Kong
Ajay Gupta
David Migneault
Original Assignee
Univ Kingston
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT00930923T priority Critical patent/ATE466571T1/en
Application filed by Univ Kingston, Neurochem Inc filed Critical Univ Kingston
Priority to CA002373093A priority patent/CA2373093C/en
Priority to EP00930923A priority patent/EP1227803B1/en
Priority to MXPA01011989A priority patent/MXPA01011989A/en
Priority to IL14668100A priority patent/IL146681A0/en
Priority to AU49050/00A priority patent/AU4905000A/en
Priority to JP2000619408A priority patent/JP2003500350A/en
Priority to DE60044365T priority patent/DE60044365D1/en
Publication of WO2000071101A2 publication Critical patent/WO2000071101A2/en
Priority to IL146681A priority patent/IL146681A/en
Publication of WO2000071101A3 publication Critical patent/WO2000071101A3/en
Priority to HK03100829.4A priority patent/HK1050133A1/en
Priority to IL180523A priority patent/IL180523A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.
PCT/CA2000/000607 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits WO2000071101A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU49050/00A AU4905000A (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits
CA002373093A CA2373093C (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits
EP00930923A EP1227803B1 (en) 1999-05-24 2000-05-24 compounds for inhibiting iapp-associated amyloid deposits
MXPA01011989A MXPA01011989A (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits.
IL14668100A IL146681A0 (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits
AT00930923T ATE466571T1 (en) 1999-05-24 2000-05-24 COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITION
JP2000619408A JP2003500350A (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits
DE60044365T DE60044365D1 (en) 1999-05-24 2000-05-24 LOID DEPOSIT
IL146681A IL146681A (en) 1999-05-24 2001-11-22 Use of iapp-inhibiting compounds for the manufacture of medicaments for inhibiting or reducing amyloid deposits
HK03100829.4A HK1050133A1 (en) 1999-05-24 2003-02-05 Methods and compounds for inhibiting amyloid deposits
IL180523A IL180523A0 (en) 1999-05-24 2007-01-03 Compositions for iapp-inhibition and uses thereon

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13554599P 1999-05-24 1999-05-24
US60/135,545 1999-05-24
US14312399P 1999-07-09 1999-07-09
US60/143,123 1999-07-09
US09/576,677 2000-05-23
US09/576,677 US6562836B1 (en) 1999-05-24 2000-05-23 Methods and compounds for inhibiting amyloid deposits

Publications (2)

Publication Number Publication Date
WO2000071101A2 WO2000071101A2 (en) 2000-11-30
WO2000071101A3 true WO2000071101A3 (en) 2001-12-06

Family

ID=27384726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000607 WO2000071101A2 (en) 1999-05-24 2000-05-24 Methods and compounds for inhibiting amyloid deposits

Country Status (13)

Country Link
US (3) US6562836B1 (en)
EP (1) EP1227803B1 (en)
JP (1) JP2003500350A (en)
CN (1) CN100435785C (en)
AT (1) ATE466571T1 (en)
AU (1) AU4905000A (en)
CA (2) CA2684016A1 (en)
DE (1) DE60044365D1 (en)
HK (1) HK1050133A1 (en)
IL (3) IL146681A0 (en)
MX (1) MXPA01011989A (en)
NZ (3) NZ541238A (en)
WO (1) WO2000071101A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
AU4282400A (en) * 1999-04-28 2000-11-10 Neurochem (International) Limited Compositions and methods for treating amyloidosis
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
WO2003029169A2 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
KR100948278B1 (en) * 2002-02-07 2010-03-18 히토시 엔도 Aromatic amino acid derivatives and medicinal compositions
WO2004058686A1 (en) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
PT1511710E (en) * 2002-05-31 2014-02-26 Proteotech Inc Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
US20040167183A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
CA2521189A1 (en) * 2003-04-11 2004-10-28 Gabor Tigyi Lysophosphatidic acid analogs and inhibition of neointima formation
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
AU2004249527A1 (en) * 2003-06-23 2004-12-29 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
CN100528840C (en) * 2003-06-23 2009-08-19 贝卢斯健康(国际）有限公司 Improved drug and its preparing method
SI1646659T1 (en) * 2003-06-23 2014-07-31 Kiacta Sarl Method for the preparation of 1,3-propane disulfonic acid compounds
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005079830A1 (en) * 2004-02-23 2005-09-01 Paul Fraser Inhibitors of amyloid fibril formation and uses thereof
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
BRPI0517790A (en) * 2004-11-12 2008-10-21 Neurochem Int Ltd fluorinated methods and compositions for treating amyloid-related diseases
EP1817305A2 (en) * 2004-11-16 2007-08-15 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
EP1836161B1 (en) * 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
EP1874285B1 (en) * 2005-04-07 2009-10-07 Astrum Therapeutics Pty, Ltd. Complementary compositions to reduce blood glucose levels and treat diabetes
WO2006110477A2 (en) * 2005-04-07 2006-10-19 Astrum Therapeutics Pty. Ltd. Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2006125324A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
US20070049638A1 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
PT3851447T (en) 2006-10-12 2023-12-11 Bellus Health Inc Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
CA2671904C (en) * 2006-12-06 2012-07-03 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
AU2007337806A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR101755178B1 (en) * 2008-11-14 2017-07-06 비에이치아이 리미티드 파트너쉽 Organic nutrient salts, methods of preparation and uses
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
CA2760837C (en) * 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CN102638982B (en) 2009-05-12 2015-07-08 百时美施贵宝公司 Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (en) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
IN2012DN00352A (en) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2464626A4 (en) 2009-08-10 2015-12-16 Bhi Ltd Partnership Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid
CN102573794B (en) 2009-08-19 2017-03-15 康奈尔大学 Cysteine for physiologic infusion
US20130143804A1 (en) * 2010-06-07 2013-06-06 Trustees Of The University Of Pennsylvania Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus
MX357628B (en) 2010-08-16 2018-07-17 Cognoptix Inc Star SYSTEM and METHOD FOR DETECTING AMYLOID PROTEINS.
EP2714682B1 (en) 2011-05-24 2016-03-16 Università degli Studi di Bari "Aldo Moro" Novel tetrahydroisoquinoline compounds for use in the diagnosis and treatment of neurodegenerative diseases
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
SI3052096T1 (en) 2013-10-03 2018-04-30 Kura Oncology, Inc. Inhibitors of erk and methods of use
WO2016196591A1 (en) * 2015-06-01 2016-12-08 Indiana University Research & Technology Corporation Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
US10654802B2 (en) * 2016-07-08 2020-05-19 Arizona Board Of Regents On Behalf Of The Unversit Indoline derivatives and method for using and producing the same
US20230148589A1 (en) * 2020-03-31 2023-05-18 Lg Chem, Ltd. Composition for protecting islet transplantation

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872125A (en) * 1973-03-03 1975-03-18 Sandoz Ag 3-substituted-4-aryl isoquinolines
EP0236251A2 (en) * 1986-03-05 1987-09-09 Universite Louis Pasteur (Strasbourg I) 2-(2-aminobenzyl)-1,2,3,4-tetrahydroisoquinolines, processes for obtaining them and pharmaceutical compositions containing them
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
DE4313118A1 (en) * 1993-04-22 1994-10-27 Hoechst Ag Use of 1,2,3,4-tetrahydroisoquinoline derivatives as antimycotics
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus
WO1997009976A2 (en) * 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
WO2000006133A2 (en) * 1998-07-28 2000-02-10 Neurochem, Inc. Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
WO2000057707A1 (en) * 1999-03-15 2000-10-05 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384751A1 (en) 1977-03-23 1978-10-20 Francaise Coop Pharma NEW DERIVATIVES OF TAURINE WITH ENHANCED NEUROMUSCULAR ACTIVITY
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
FR2457281A1 (en) 1979-05-23 1980-12-19 Meram Lab NOVEL 3-AMINOPROPANESULFONIC ACID DERIVATIVES WITH ENHANCED MEMBRANE ACTIVITY
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
FR2529546A1 (en) 1982-07-05 1984-01-06 Meram Lab NOVEL N-SUBSTITUTED A, O-SULFONIC AMINO- (AND IMINO-) ACIDS, CATIONIC VECTORS OF HIGH CELL PENETRATION
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1193590B (en) 1983-01-07 1988-07-08 Loris Jacopo Bononi AMINO-ALCHYL-SULPHONIC DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
SE454299B (en) * 1986-10-08 1988-04-18 Westermark P RATE OF POLYPEPTIDE CONTAINED IN PANCREASOAMYLOID AND / OR ANTIBODIES TARGETED TO THE POLYPEPTIDE
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE3940410A1 (en) 1989-12-04 1991-06-06 Schering Ag NEW USE OF NMDA RECEPTOR ANTAGONISTS
FR2657164B1 (en) 1990-01-16 1992-04-03 Cit Alcatel LEAK DETECTION INSTALLATION WITH INTERMEDIATE HOLWECK PUMP.
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
DE4021066A1 (en) 1990-07-03 1992-01-09 Hoechst Ag LONG-TERM PROPHYLAXIS AGAINST DISEASES CAUSED BY VIRUSES OR BY UNCONVENTIONAL VIRUSES
DE69232909D1 (en) 1991-02-22 2003-03-06 Howard K Shapiro USE OF PHARMACEUTICAL ACTIVE SUBSTANCES FOR THE TREATMENT OF DISEASE SYMPTOMS, NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMS COMPLEXES
IT1245907B (en) * 1991-05-17 1994-10-25 Alfa Wassermann Spa USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY.
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
EP0611966A1 (en) * 1993-02-19 1994-08-24 Bayer Corporation Method, composition and device for measuring the ionic strength or specific gravity of a test sample
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
AU6836394A (en) 1993-06-01 1994-12-20 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
US5576419A (en) * 1993-06-30 1996-11-19 Regents Of The University Of Minnesota Mild solid-phase synthesis of aligned branched triple-helical peptides
WO1995006477A1 (en) 1993-08-31 1995-03-09 Gliatech, Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
CA2242851A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
JPH0995444A (en) * 1995-10-02 1997-04-08 Teijin Ltd Agent for inhibiting agglomeration of amyloid protein
US5972956A (en) 1995-11-02 1999-10-26 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US5927328A (en) * 1996-09-26 1999-07-27 Masco Corporation Self closing faucet with timing mechanism
KR20000036227A (en) 1996-09-27 2000-06-26 토마스 씨. 서 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
SE9604582D0 (en) 1996-12-13 1996-12-13 Astra Ab Novel compounds
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
WO1999008685A1 (en) * 1997-08-18 1999-02-25 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
CA2301725C (en) * 1997-08-28 2008-11-18 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6166320A (en) * 1998-03-19 2000-12-26 Toyota Jidosha Kabushiki Kaisha Tandem solar cell
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872125A (en) * 1973-03-03 1975-03-18 Sandoz Ag 3-substituted-4-aryl isoquinolines
EP0236251A2 (en) * 1986-03-05 1987-09-09 Universite Louis Pasteur (Strasbourg I) 2-(2-aminobenzyl)-1,2,3,4-tetrahydroisoquinolines, processes for obtaining them and pharmaceutical compositions containing them
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
DE4313118A1 (en) * 1993-04-22 1994-10-27 Hoechst Ag Use of 1,2,3,4-tetrahydroisoquinoline derivatives as antimycotics
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus
WO1997009976A2 (en) * 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
WO2000006133A2 (en) * 1998-07-28 2000-02-10 Neurochem, Inc. Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
WO2000057707A1 (en) * 1999-03-15 2000-10-05 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAURES, PAUL W. ET AL: "Discovering transthyretin amyloid fibril inhibitors by limited screening", BIOORG. MED. CHEM. (1998), 6(8), 1389-1401, XP002129747 *
GEORGIEV, V. S. ET AL: "Drug-induced modifications of the immune response. 1. Substituted 1-phenylisoquinolines", J. MED. CHEM. (1979), 22(4), 348-52, XP000992891 *
MALMUSI L ET AL: "1,2,3,4-TETRAHYDROISOQUINOLINE AND RELATED ANALOGS OF THE PHENYLALKYLAMINE DESIGNER DRUG MDMA", MEDICINAL CHEMISTRY RESEARCH,BIRKHAEUSER, BOSTON,US, vol. 6, no. 6, 1996, pages 412 - 426, XP000978322, ISSN: 1054-2523 *
O'BRIEN T D ET AL: "HUMAN ISLET AMYLOID POLYPEPTIDE EXPRESSION IN COS-1 CELLS A MODEL OF INTRACELLULAR AMYLOIDOGENESIS", AMERICAN JOURNAL OF PATHOLOGY,US,PHILADELPHIA, PA, vol. 147, no. 3, 1 September 1995 (1995-09-01), pages 609 - 616, XP000590832, ISSN: 0002-9440 *
POWELL D S (REPRINT) ET AL: "Insulin and polyionic sulphonates modify human islet amyloid polypeptide fibril aggregation in vitro", DIABETOLOGIA, (AUG 1998) VOL. 41, SUPP. [1], PP. 656-656. PUBLISHER: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010. ISSN: 0012-186X., RADCLIFFE INFIRM, DIABET RES LABS, OXFORD OX2 6HE, ENGLAND;UNIV OXFORD, DEPT HUMAN ANAT, OXFORD OX1 3QX, ENGLAND; UNIV TORONTO, CNDR, TORONTO, ON, CANADA; QUEENS UNIV, DEPT CHEM, KINGSTON, ON K7L 3N6,, XP000978398 *

Also Published As

Publication number Publication date
US7786174B2 (en) 2010-08-31
IL146681A0 (en) 2002-07-25
IL180523A0 (en) 2009-02-11
NZ566739A (en) 2009-10-30
EP1227803B1 (en) 2010-05-05
US7393875B2 (en) 2008-07-01
JP2003500350A (en) 2003-01-07
CA2373093C (en) 2010-01-19
CN1377260A (en) 2002-10-30
ATE466571T1 (en) 2010-05-15
WO2000071101A2 (en) 2000-11-30
NZ541238A (en) 2007-02-23
DE60044365D1 (en) 2010-06-17
US6562836B1 (en) 2003-05-13
MXPA01011989A (en) 2002-05-06
EP1227803A2 (en) 2002-08-07
CA2373093A1 (en) 2000-11-30
AU4905000A (en) 2000-12-12
CA2684016A1 (en) 2000-11-30
US20080227767A1 (en) 2008-09-18
NZ552354A (en) 2008-04-30
IL146681A (en) 2007-12-03
US20040248876A1 (en) 2004-12-09
CN100435785C (en) 2008-11-26
HK1050133A1 (en) 2003-06-13

Similar Documents

Publication Publication Date Title
WO2000071101A3 (en) Methods and compounds for inhibiting amyloid deposits
AU3664401A (en) Platelet adp receptor inhibitors
WO2003051313A3 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
WO2002085303A3 (en) Substituted tetracycline compounds for the treatment of malaria
BR0211119A (en) Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
CA2427227A1 (en) Lactam compound
IL128568A0 (en) Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
BR0213139A (en) Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
EP1022026A3 (en) Pharmaceutical compositions for treating nitrate-induced tolerance
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO1998008505A8 (en) Pharmaceutical compounds
MXPA03011466A (en) Macrocycles useful in the treatment of alzheimer's disease.
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
BR0115424A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating alzheimer's disease, for preventing alzheimer's disease, and for inhibiting the progress of alzheimer's disease, processes for preparing the compound , and to prepare lactams, and, use of compound
CA2198580A1 (en) Combination therapy to treat osteoporosis
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
MXPA03000166A (en) Preparation of phosphatase inhibitors.
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2373093

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011989

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 619408

Country of ref document: JP

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 516377

Country of ref document: NZ

Ref document number: 49050/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000930923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008107203

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000930923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 180523

Country of ref document: IL